HTG Therapeutics

HTG Therapeutics is focused on utilizing its innovative technology platforms to create an entirely new generation of drug discovery tools aimed at developing therapeutic candidates with superior efficacy and safety profiles - transforming the process across a broad range of disease areas including oncology, immunology, diabetes, and rare diseases, among others.

HTG EdgeSeq and Epi-EdgeSeq technology enables a more highly resolved view of the transcriptome, especially aberrations in the physiological states leading to disease. By assimilating sophisticated RNA profiling and advanced medical chemistry technologies directly - and early-on - in the process, researchers can access critical learnings much sooner, significantly reduce risk, and increase successful outcomes.


HTG Therapeutics leverages its transcriptomic and epi-transcriptomic profiling technology to dramatically transform the drug discovery process. HTG's platform currently produces a profile with nearly 42,000 data points per sample in three independent data sets and has the ability to detect changes in RNA modifiations, such as N6-methyladenosine (m6A), which has been increasingly implicated in various disease states.

Learn More

Drug Discovery Process


By leveraging HTG's unique profiling technologies earlier in the drug discovery process, HTG Therapeutics is expected to generate lead compounds faster, and with superior efficacy and toxicity profiles.

Learn More


Drug Discovery Pipeline

HTG Therapeutics will identify development candidates targeting RNA and RNA-modifying proteins, targets relevant in a wide range of diseases of unmet therapeutic need. The profiling of these diseases using the HTG EdgeSeq technology is an essential element in guiding these efforts. From hit to lead clinical candidate- HTG seeks to bring to the forefront the power of transcriptome profiling and data science to generate insights factoring into the selection of improved therapeutic candidates entering clinical trials.

Learn More

HTG Therapeutics News & Events

HTG and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collaboration

HTG’s Innovative Transcriptome Panel Technology to be Leveraged in Retrospective Studies TUCSON, Ariz. , Nov. 17, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling…

Keep Reading

HTG Molecular Diagnostics Reports Third Quarter 2021 Results

Call scheduled for today, November 10, at 4:30 pm ET TUCSON, Ariz. , Nov. 10, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its…

Keep Reading

HTG Molecular Diagnostics to Announce Third Quarter 2021 Financial Results and Host Conference Call on Wednesday, November 10

TUCSON, Ariz. , Nov. 02, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company advancing precision medicine through its transcriptome-wide technology, today announced that it will report its financial results for the third quarter ended September 30, 2021…

Keep Reading

Page last updated November 09, 2021